Advertisement

Topics

Latest "Ramsell Technologies" News Stories

06:32 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "Ramsell Technologies" found in our extensive news archives from over 250 global news sources.

More Information about Ramsell Technologies on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Ramsell Technologies for you to read. Along with our medical data and news we also list Ramsell Technologies Clinical Trials, which are updated daily. BioPortfolio also has a large database of Ramsell Technologies Companies for you to search.

Showing "Ramsell Technologies" News Articles 1–25 of 4,700+

Tuesday 18th December 2018

StemCell Technologies Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryStemCell Technologies Inc StemCell is a biotechnology company that develops cell separation systems, instruments and other reagents for use in life sciences research. The company's products comprise specialized cell culture media and supplements, cell isolation products, antibodies; primary and cultured cells, mammalian cloning products, small molecules, cryopreservation media, cytokines, c...


Icon Genetics GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryIcon Genetics GmbH Icon Genetics, a subsidiary of Denka Co Ltd, is a technology company that offers plant engineering technologies. The company develops, manufactures and markets biopharmaceutical product candidates, engineered organisms and technology platforms for plant biotechnology and plantbased production. It commercializes proprietary transgene operating systems suites of technologie...

Horizon Discovery Group plc enters an exclusive partnership with C4X Discovery Holdings plc to validate targets and develop next-generation oncology drugs

Cambridge, UK, 17 December 2018: Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) ("C4XD"), a pioneering drug discovery company. The partnership aims to validate the novel synthetic ...


Monday 17th December 2018

Opinion: Asking the industry to identify "emerging technologies" acknowledges that the government is no longer pushing the state of the art. It's also an opportunity for companies across the sectors to shape their fates. https://buff.ly/2QAQdUg 

Opinion: Asking the industry to identify "emerging technologies" acknowledges that the government is no longer pushing the state of the art. It's also an opportunity for companies across the sectors to shape their fates. https://buff.ly/2QAQdUg 

SHAREHOLDER ALERT: Monteverde Associates PC Announces An Investigation Of L3 Technologies, Inc. ...

NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Read more...

Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in Celebration of IPO Closing

Aptorum Group Limited (“APM”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, announced today that its management will visit the Nasdaq MarketSite in Times Square, in celebration of the closing of its...

Aptorum Group Limited Announces Closing of Initial Public Offering

Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419...

Covalon Announces Fiscal 2018 Year-End Results and Plans for Fiscal 2019

Fiscal 2018 profitable with $0.07 EPS on $26.7 million of revenue. Fiscal 2019 contracted Middle East revenue expected to be approximately $30 million, more than double the contracted revenue of fiscal 2018. Fiscal 2019 acquisition of AquaGuard more than doubles United States revenue to approximately $25 million...

Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants

Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the issuance of European patent No. 3008186, which claims methods to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR/Cas9. This patent, granted by the European Patent Office, is owned by Cellect...

Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics

PTX-022 is a late-stage drug candidate targeting pachyonychia congenita Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics. PTX-022 is a novel, topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita (PC), a rare ...

Introducing the Largest Smart City Event in Asia: Smart City Summit & Expo in March 2019

TAIPEI, Taiwan, Dec. 17, 2018 /PRNewswire/ -- 2019 Smart City Summit & Expo (SCSE), Asia's largest annual smart city tradeshow, will be held in Taipei, Taiwan, March 26 to 29. Jointly organized by Taipei City Government, Taiwan Smart City Solutions Alliance, and Taipei Computer Association, SCSE has invited professionals from all around the world to share their experiences in smart city develo...

Canadian university launches center to build AI 'machines with morals'

The University of Guelph in Ontario, Canada, has launched a new center that aims to address the ethics of AI and build "machines with morals" by ensuring technologies benefit people and minimize harm.

Fujifilm India organises 2─day breast cancer conference to spread awareness on relevance of early detection

Reinforcing its commitment towards being a socially responsible brand, Fujifilm India Pvt Ltd, a leader in the development and application of imaging and information innovations to healthcare technologies

Pratt Whitney GTF™ Engine Repair Supplier Network Continues to Expand

EAST HARTFORD, Conn., Dec. 17, 2018 /PRNewswire/ -- Pratt & Whitney, a division of United Technologies Corp. (NYSE: UTX), today announced that it will further Read more...

ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2019 Cohort of Life Science Startups

12 High-Potential Companies Selected for ABCT BRANFORD, Conn. (PRWEB) December 17, 2018 ABCT, the Accelerator for Biosciences in Connecticut, announced today the second cohort of emerging biosciences ventures invited to participate in the annual program. Twelve ventures will participate in the 6.5-month-long program that features business education to develop fundable business plans and a profess...

A New Edition of Hastings Center Report Is Now Available

Hastings Center Report (vol. 48, no. S2, 2018) is available online by subscription only. Articles include: “Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies” by Josephine Johnston  

Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma

Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). This collaboration with AKP was initiated in October 2013 and utilises Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid art...

Viewpoints: Lessons On Stopping E. Coli Outbreaks; Government Steps Up To Monitor Emerging Technologies

Editorial pages focus on these health care issues and others.

New education program to accelerate industry next-gen processing

Employee training is critical as organizations implement next-generation technologies to create new products and streamline their operations across departments.  

Namaste Technologies increases stake in Pineapple Express to 49%

Namaste Technologies (CVE:N) (OTCMKTS:NXTTF) CEO Sean Dollinger tells Proactive Investors the cannabis company is acquiring a 49% stake in Pineapple Express Delivery Inc, a company that offers a same-day delivery service platform for medical and recreational cannabis to Canadian licensed producers. Dollinger says the reason why the company increased its stake in the company to just 49% from 15...

Teneobio and Selexis Enter Second Services Agreement to Develop Research Cell Banks as Teneobio Prepares to Advance Three Additional Oncology-Targeting Multi-Specific UniAbs into the Clinic

Selexis SA and Teneobio, Inc. announced today that they have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heav

Titan Medical Expands Global Patent Portfolio for Single-Port Robotic Surgery with Seven Grants and Notices of Allowance

Titan Medical Inc. (TSX:TMD) (Nasdaq:TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces seven new patent grants and notices of allowance related to its single-port robotic surgery technology, including patents ...

Covalon Announces Conference Call to Discuss Year-End and Fourth Quarter Financial Results

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV; OTCQX:CVALF), an advanced medical technologies company, will release its Fiscal 2018 Fourth Quarter and Year-End financial results concurrently on Monday December 17th, 2018, after markets close. A conference call to discuss the financial results will be held Tuesday Dece...

AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.

AmorChem announces today the creation of MyX Therapeutics Inc, its sixth spin-off company focusing on MyX-001, a biodegradable muco-adhesive nanoparticle delivery platform, capable of sustained drug releases for ophthalmic use and other mucosa-based deliveries. All rights to the MyX-001 technology initially held by AmorChem have been transferred to MyX The...

Hardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics

Hardman & Co Research 17-Dec-2018 / 11:56 GMT/BST Hardman & Co: 2018 in review: foundations laid for osteobiologics TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). With organic growth being b...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks